Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
12.76
-1.48 (-10.39%)
At close: Sep 3, 2026, 4:00 PM EDT
12.95
+0.19 (1.49%)
Pre-market: Sep 4, 2026, 7:49 AM EDT
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
174.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 80.62M |
| Precision BioSciences | 45.06M |
| Cue Biopharma | 37.66M |
| LENZ Therapeutics | 21.48M |
| Alpha Cognition | 15.26M |
| Innate Pharma | 10.57M |
| Armata Pharmaceuticals | 5.54M |
| Veraxa Biotech AG | 29.54K |
IMUX News
- 2 days ago - Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 - PRNewsWire
- 3 days ago - Immunic price target raised to $29 from $19 at Roth Capital - TheFly
- 3 days ago - Immunic appoints Chitrang Dave as chief data, digital officer - TheFly
- 3 days ago - Immunic Appoints Chitrang Davé as Chief Data and Digital Officer - PRNewsWire
- 18 days ago - Immunic initiated with an Outperform at Wedbush - TheFly
- 23 days ago - Immunic Earnings release: Q2 2026 - Filings
- 23 days ago - Immunic Quarterly report: Q2 2026 - Filings
- 24 days ago - Immunic reports Q2 EPS (80c), consensus ($1.16) - TheFly